A Phase 2 interventional study of Fazisiran Injection and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 21st largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2019, is one of 20 in phase 2, and was the 57th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Tessera Therapeutics, Inc. · Sites in United States, Australia, Netherlands and 2 more countries
Ages 18–70
University of Alabama at Birmingham · Sites in United States
Ages 19+
Columbia University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 11 · Phase 4 4
First in 1995; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 55 interventional studies, 190 across the 26 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 13 (54%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in alpha 1-Antitrypsin Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05297812Columbia UniversityAlpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | 2027-01 |
| NCT07135427University of Alabama at BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Participants will be enrolled to receive multiple subcutaneous injections of Fazirsiran Injection (also referred to as TAK-999 Injection or ARO-AAT Injection) or placebo. Eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. However, any participant with a biopsy result within 1 year of screening showing no fibrosis does not require a pre-dose biopsy. Only participants who have liver fibrosis will undergo a post-dose biopsy and may continue treatment in an open-label phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind (DB) Period: Participants with no fibrosis: Administered on Day 1 and Week 4. Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. Open-label (OL) Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 25 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.
Drug: Fazisiran Injection
DB Period: Participants with no fibrosis: Fazirsiran 100 mg administered on Day 1 and Week 4. Participants with fibrosis: Fazirsiran 100 mg administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 100 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.
Drug: Fazisiran Injection
DB Period: Participants with no fibrosis: Fazirsiran 200 mg administered on Day 1 and Week 4. Participants with fibrosis: Fazirsiran 200 mg administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 200 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study
Drug: Fazisiran Injection
DB Period: Participants with no fibrosis: Placebo administered on Day 1 and Week 4. Participants with fibrosis: Placebo administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) placebo and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.
Drug: Fazisiran Injection · Other: Placebo
solution for subcutaneous (sc) injection
Also known as: ARO-AAT Injection, TAK-999 Injection
sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16
Time frame: Baseline, Week 16 (+/- 2 weeks)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Phase
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
Time frame: Double Blind Phase (up to Week 48): dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Phase
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
Time frame: From dose administration of the first dose of open-label phase fazirsiran through EOS or Early Termination (up to Week 196).
Absolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Percent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Absolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Percent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Absolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Percent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Absolute Change From Baseline in Liver Function Tests: Alanine Aminotransferase (ALT) at Week 16 and Over Time Through End of Study (EOS)
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: ALT at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Aspartate Aminotransferase (AST) at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: AST at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Alkaline Phosphatase (ALP) at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: ALP at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Gamma Glutamyl Transferase (GGT) at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: GGT at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Absolute Change in Serum Z-AAT Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Percent Change in Serum Z-AAT Over Time Through EOS
PDLB=post-dose liver biopsy
Time frame: Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Pharmacokinetics (PK): ARO-AAT Plasma Concentration Summary for the Double-Blind Phase
Time frame: Fazirsiran participants without fibrosis: Pre-dose, 1 hour, 2 hour, 24 hours post-dose on Day 1 (+/- 1 day). Fazirsiran participants with fibrosis: Pre-dose, 1 hour, 2 hours, 24 hours post-dose on Day 1 and Week 16 (+/- 1 day).
Number of Participants Positive for Anti-Drug Antibodies to Fazirsiran
PDLB=post-dose liver biopsy
Time frame: Baseline, Weeks 4, 16, 28, 40, 48, 52, 64, 76, 88, 96, 100, 112, 124, 136, 148 or Early Termination (up to 148 weeks)
Percentage of Participants With Shifts From Baseline in METAVIR Fibrosis Stage at Post-Dose Biopsy for Participants With Fibrosis
The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. The stage represents the amount of fibrosis or scarring: 0= no fibrosis; 1=portal fibrosis without septa; 2=portal fibrosis with few septa; 3=numerous septa without cirrhosis; 4=cirrhosis. A higher score indicates a worse condition.
Time frame: Baseline, Post-dose at Weeks 48 (+/- 2 weeks) or Week 72 (+/- 4 weeks) or Week 96 (+/- 4 weeks)
| Milestone | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Fazirsiran 25 mg DB/200 mg OL | Fazirsiran 100 mg DB/200 mg OL | Fazirsiran 200 mg DB/200 mg OL | Placebo DB / Fazirsiran 200 mg OL |
|---|---|---|---|---|---|---|---|---|
| Started | 9 | 8 | 9 | 14 | 0 | 0 | 0 | 0 |
| Completed | 8 | 8 | 7 | 14 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Fazirsiran 25 mg DB/200 mg OL | Fazirsiran 100 mg DB/200 mg OL | Fazirsiran 200 mg DB/200 mg OL | Placebo DB / Fazirsiran 200 mg OL |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 4 | 5 | 5 | 9 |
| Completed | 0 | 0 | 0 | 0 | 4 | 5 | 5 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16 | -62.17 ± 4.279 | -85.39 ± 4.634 | -92.93 ± 4.341 | 4.64 ± 3.211 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
| Participants | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| TEAEs | 9 | 8 | 9 | 14 |
| TESAEs | 0 | 0 | 2 | 3 |
| TEAEs Leading to Withdrawal of Study Drug | 0 | 0 | 1 | 0 |
| TEAEs Leading to Study Termination | 0 | 0 | 1 | 0 |
| TEAEs Leading to Death | 0 | 0 | 0 | 0 |
| TEAEs by Worst Severity: Mild | 3 | 2 | 1 | 5 |
| TEAEs by Worst Severity: Moderate | 6 | 6 | 6 | 6 |
| TEAEs by Worst Severity: Severe | 0 | 0 | 2 | 3 |
| TEAEs by Worst Relationship: Not Related | 7 | 4 | 5 | 6 |
| TEAEs by Worst Relationship: Possibly Related | 2 | 3 | 1 | 8 |
| TEAEs by Worst Relationship: Probably Related | 0 | 1 | 3 | 0 |
| TEAEs by Worst Relationship: Possibly or Probably | 2 | 4 | 4 | 8 |
| TEAE at Injection Site | 1 | 1 | 2 | 2 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
| Participants | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| TEAEs | 4 | 4 | 3 | 9 |
| TESAEs | 1 | 1 | 1 | 1 |
| TEAEs Leading to Withdrawal of Study Drug | 0 | 0 | 0 | 1 |
| TEAEs Leading to Study Termination | 0 | 0 | 0 | 1 |
| TEAEs Leading to Death | 0 | 0 | 0 | 0 |
| TEAEs by Worst Severity: Mild | 3 | 2 | 0 | 7 |
| TEAEs by Worst Severity: Moderate | 0 | 1 | 3 | 1 |
| TEAEs by Worst Severity: Severe | 1 | 1 | 0 | 1 |
| TEAEs by Worst Relationship: Not Related | 2 | 0 | 3 | 7 |
| TEAEs by Worst Relationship: Possibly Related | 2 | 3 | 0 | 2 |
| TEAEs by Worst Relationship: Probably Related | 0 | 1 | 0 | 0 |
| TEAEs by Worst Relationship: Possibly or Probably | 2 | 4 | 0 | 2 |
| TEAE at Injection Site | 1 | 1 | 0 | 0 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| nmol/g | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Absolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis | -89.341 ± 94.832 | -259.892 ± 330.199 | -29.371 ± 22.867 | -4.738 ± 57.342 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis | -86.89 ± 29.658 | -81.61 ± 29.503 | -98.16 ± 23.256 | 42.42 ± 21.133 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| nmol/g | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Absolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis | -20.427 ± 15.042 | -109.747 ± 135.114 | -17.418 ± 4.860 | 2.300 ± 12.940 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis | -75.73 ± 16.645 | -87.23 ± 17.064 | -95.71 ± 12.824 | 22.33 ± 11.890 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| nmol/g | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Absolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis | -68.914 ± 80.725 | -150.145 ± 196.675 | -11.953 ± 18.602 | -7.038 ± 47.041 |
Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis | -86.36 ± 60.305 | -72.44 ± 58.358 | -101.85 ± 47.495 | 91.35 ± 42.750 |
PDLB=post-dose liver biopsy
| U/L | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -3.0 ± 9.17 | -2.4 ± 5.42 | -8.4 ± 15.88 | 1.7 ± 6.60 |
| Week 16 + 24 H | -7.3 ± 11.93 | -3.8 ± 3.59 | -2.2 ± 2.86 | 0.8 ± 5.31 |
| Week 28 | -10.7 ± 4.57 | -5.8 ± 9.56 | 0.6 ± 6.48 | 1.0 ± 6.91 |
| Week 40 | -4.6 ± 9.07 | -5.0 ± 8.78 | 3.1 ± 9.79 | -0.1 ± 4.66 |
| PDLB at Week 48 | -10.5 ± 10.47 | 0.0 ± 16.00 | -2.2 ± 5.31 | 3.3 ± 7.71 |
| Week 52 | -1.5 ± 12.31 | -6.0 ± 7.39 | 12.3 ± 33.80 | -0.4 ± 4.44 |
| Week 64 | -9.8 ± 8.50 | -14.3 ± 8.88 | -0.3 ± 8.30 | 5.7 ± 15.48 |
| PDLB at Week 72 | — | — | — | -6.0 ± NA |
| Week 76 | -7.3 ± 3.06 | -14.8 ± 9.07 | 3.5 ± 8.24 | 7.7 ± 8.85 |
| Week 88 | -9.0 ± 3.46 | -18.5 ± 9.19 | 4.8 ± 4.97 | 6.2 ± 7.76 |
| PDLB at Week 96 | — | -21.0 ± 5.66 | 12.0 ± NA | 10.0 ± 12.73 |
| Week 100 | -9.0 ± 2.83 | -21.5 ± 9.19 | 7.5 ± 7.78 | 1.3 ± 9.43 |
| Week 112 | -8.0 ± NA | -18.0 ± 7.07 | 8.0 ± 4.24 | -0.3 ± 6.43 |
| Week 124 | — | -18.0 ± 4.24 | 7.0 ± NA | 5.0 ± 11.53 |
| Week 136 | — | — | 4.0 ± NA | 8.3 ± 17.90 |
| Week 148 | — | — | 11.0 ± NA | 4.3 ± 14.98 |
| Week 160 | — | — | — | 23.0 ± 4.24 |
| Early Termination | — | — | -2.0 ± 9.90 | — |
| End of Study | 7.0 ± 16.64 | -1.0 ± 5.66 | -0.5 ± 4.95 | -0.2 ± 5.45 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -9.6 ± 20.1 | -4.3 ± 19.9 | -15.3 ± 16.2 | 5.8 ± 16.1 |
| Week 16 + 24 H | -15.7 ± 24.8 | -9.7 ± 8.9 | -10.8 ± 17.6 | 0.5 ± 13.3 |
| Week 28 | -27.4 ± 8.5 | -12.4 ± 25.1 | 2.0 ± 29.3 | 6.4 ± 21.9 |
| Week 40 | -11.2 ± 21.4 | -13.0 ± 24.0 | 4.0 ± 20.0 | 2.9 ± 18.3 |
| PDLB at Week 48 | -21.7 ± 19.1 | -1.2 ± 38.2 | -4.8 ± 20.5 | 5.9 ± 15.2 |
| Week 52 | -1.6 ± 32.9 | -15.2 ± 18.1 | 14.5 ± 28.5 | -1.4 ± 14.8 |
| Week 64 | -22.3 ± 20.3 | -33.3 ± 15.5 | 4.4 ± 35.8 | 11.0 ± 29.3 |
| PDLB at Week 72 | — | — | — | -14.3 ± NA |
| Week 76 | -20.0 ± 7.0 | -33.7 ± 16.2 | 24.6 ± 43.6 | 26.3 ± 34.1 |
| Week 88 | -24.1 ± 0.0 | -39.8 ± 15.9 | 28.2 ± 32.6 | 20.7 ± 28.6 |
| PDLB at Week 96 | — | -45.7 ± 7.5 | 60.0 ± NA | 44.8 ± 58.7 |
| Week 100 | -31.0 ± 9.8 | -46.4 ± 15.2 | 38.1 ± 38.1 | 9.9 ± 24.1 |
| Week 112 | -27.6 ± NA | -38.9 ± 11.3 | 41.4 ± 19.2 | 3.3 ± 24.7 |
| Week 124 | — | -39.3 ± 5.1 | 35.0 ± NA | 25.2 ± 49.4 |
| Week 136 | — | — | 20.0 ± NA | 40.1 ± 79.4 |
| Week 148 | — | — | 55.0 ± NA | 25.5 ± 61.4 |
| Week 160 | — | — | — | 88.8 ± 3.0 |
| Early Termination | — | — | -10.3 ± 65.0 | — |
| End of Study | 14.1 ± 38.7 | -6.8 ± 34.6 | -8.4 ± 15.0 | 4.7 ± 23.3 |
PDLB=post-dose liver biopsy
| U/L | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -2.9 ± 8.27 | -0.1 ± 4.02 | 1.1 ± 6.10 | 0.7 ± 5.23 |
| Week 16 + 24 H | -7.7 ± 11.59 | 0.0 ± 2.58 | 0.3 ± 3.93 | -0.4 ± 3.81 |
| Week 28 | -7.4 ± 7.31 | -1.3 ± 4.68 | 10.2 ± 27.92 | 0.1 ± 5.49 |
| Week 40 | -2.9 ± 10.78 | 2.0 ± 17.55 | 2.9 ± 8.25 | -0.9 ± 3.65 |
| PDLB at Week 48 | -12.0 ± 10.42 | 1.7 ± 4.16 | -1.0 ± 5.22 | 1.2 ± 6.40 |
| Week 52 | -2.1 ± 9.89 | -0.9 ± 8.46 | 6.3 ± 15.92 | -0.9 ± 2.93 |
| Week 64 | -8.8 ± 10.24 | -10.3 ± 10.40 | -0.7 ± 4.42 | 1.9 ± 7.70 |
| PDLB at Week 72 | — | — | — | -3.0 ± NA |
| Week 76 | -6.3 ± 4.73 | -10.3 ± 8.85 | 3.2 ± 5.78 | 7.5 ± 7.20 |
| Week 88 | -6.7 ± 5.69 | -16.5 ± 12.02 | 3.8 ± 8.29 | 4.2 ± 6.57 |
| PDLB at Week 96 | — | -11.0 ± NA | 2.0 ± NA | 5.0 ± 5.66 |
| Week 100 | -7.5 ± 2.12 | -21.5 ± 13.44 | 1.5 ± 2.12 | 0.0 ± 4.76 |
| Week 112 | -10.0 ± NA | -19.0 ± 14.14 | 0.5 ± 0.71 | -2.0 ± 7.00 |
| Week 124 | — | -16.5 ± 10.61 | -1.0 ± NA | 2.7 ± 9.29 |
| Week 136 | — | — | -2.0 ± NA | 6.7 ± 10.60 |
| Week 148 | — | — | 2.0 ± NA | 1.0 ± 11.14 |
| Week 160 | — | — | — | 10.5 ± 0.71 |
| Early Termination | — | — | -1.5 ± 4.95 | — |
| End of Study | 4.7 ± 8.33 | 1.5 ± 6.36 | 1.5 ± 9.19 | -0.2 ± 3.96 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -8.3 ± 20.0 | 2.6 ± 16.4 | 3.5 ± 22.5 | 2.5 ± 14.3 |
| Week 16 + 24 H | -16.9 ± 24.2 | 0.4 ± 7.8 | 1.5 ± 17.6 | 0.1 ± 9.8 |
| Week 28 | -19.3 ± 19.3 | -0.9 ± 14.5 | 26.8 ± 68.8 | 3.2 ± 17.4 |
| Week 40 | -4.7 ± 26.9 | 10.6 ± 43.4 | 8.3 ± 21.7 | -1.0 ± 11.4 |
| PDLB at Week 48 | -27.1 ± 20.1 | 6.0 ± 12.5 | -2.0 ± 16.2 | 3.4 ± 19.2 |
| Week 52 | -4.1 ± 27.2 | 1.9 ± 20.9 | 17.3 ± 40.3 | -2.8 ± 9.7 |
| Week 64 | -20.5 ± 23.3 | -21.4 ± 15.4 | -2.6 ± 16.8 | 9.5 ± 21.6 |
| PDLB at Week 72 | — | — | — | -5.9 ± NA |
| Week 76 | -17.1 ± 12.7 | -22.2 ± 13.9 | 11.9 ± 22.6 | 30.3 ± 32.8 |
| Week 88 | -16.4 ± 10.1 | -30.6 ± 15.7 | 18.1 ± 34.7 | 21.1 ± 29.6 |
| PDLB at Week 96 | — | -26.8 ± NA | 7.4 ± NA | 31.9 ± 39.8 |
| Week 100 | -24.6 ± 9.1 | -40.5 ± 15.8 | 5.6 ± 7.9 | 5.2 ± 16.3 |
| Week 112 | -34.5 ± NA | -35.1 ± 18.7 | 2.5 ± 3.5 | 2.8 ± 27.0 |
| Week 124 | — | -31.0 ± 12.8 | -3.7 ± NA | 25.6 ± 53.1 |
| Week 136 | — | — | -7.4 ± NA | 39.6 ± 70.4 |
| Week 148 | — | — | 7.4 ± NA | 21.8 ± 56.6 |
| Week 160 | — | — | — | 55.2 ± 25.7 |
| Early Termination | — | — | -7.3 ± 26.9 | — |
| End of Study | 13.7 ± 24.6 | 10.5 ± 35.1 | -2.7 ± 31.5 | 0.7 ± 17.1 |
PDLB=post-dose liver biopsy
| U/L | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -2.8 ± 9.98 | -4.3 ± 6.50 | -13.8 ± 14.26 | 4.9 ± 13.02 |
| Week 16 + 24 H | -9.7 ± 8.62 | -1.0 ± 2.16 | -11.7 ± 14.83 | 3.6 ± 6.62 |
| Week 28 | 0.6 ± 12.29 | -4.9 ± 6.88 | -8.4 ± 13.53 | 0.7 ± 5.51 |
| Week 40 | -1.1 ± 15.51 | -7.1 ± 6.36 | -8.3 ± 11.38 | 1.6 ± 7.43 |
| PDLB at Week 48 | -10.5 ± 16.62 | -0.3 ± 1.15 | -2.8 ± 15.69 | 1.2 ± 2.56 |
| Week 52 | -3.0 ± 15.38 | -7.6 ± 8.26 | -3.9 ± 9.36 | 1.9 ± 6.01 |
| Week 64 | -8.3 ± 22.23 | -6.5 ± 8.96 | 0.4 ± 15.66 | 2.1 ± 9.25 |
| PDLB at Week 72 | — | — | — | 5.0 ± NA |
| Week 76 | -14.0 ± 23.39 | -9.0 ± 11.58 | 0.5 ± 11.50 | 6.5 ± 11.33 |
| Week 88 | -14.7 ± 21.13 | -16.5 ± 23.33 | 3.0 ± 21.25 | 8.4 ± 8.02 |
| PDLB at Week 96 | — | -11.5 ± 13.44 | 2.0 ± NA | 7.0 ± 19.80 |
| Week 100 | -23.0 ± 26.87 | -11.5 ± 17.68 | -2.0 ± 2.83 | 8.8 ± 12.04 |
| Week 112 | -4.0 ± NA | -6.0 ± 11.31 | -2.0 ± 4.24 | 5.0 ± 13.75 |
| Week 124 | — | -4.0 ± 5.66 | 4.0 ± NA | 4.3 ± 9.24 |
| Week 136 | — | — | 2.0 ± NA | 7.0 ± 25.16 |
| Week 148 | — | — | 15.0 ± NA | 11.0 ± 26.46 |
| Week 160 | — | — | — | 23.0 ± 26.87 |
| Early Termination | — | — | -0.5 ± 17.68 | — |
| End of Study | 1.8 ± 10.40 | -6.0 ± 0.00 | 5.0 ± 9.90 | 3.4 ± 11.76 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -0.5 ± 12.8 | -5.6 ± 8.7 | -17.7 ± 16.0 | 5.8 ± 14.7 |
| Week 16 + 24 H | -8.9 ± 6.1 | -1.2 ± 2.8 | -14.8 ± 16.8 | 5.9 ± 10.0 |
| Week 28 | 5.5 ± 20.1 | -6.4 ± 9.3 | -10.5 ± 16.1 | 1.0 ± 7.2 |
| Week 40 | 2.0 ± 16.9 | -9.3 ± 8.2 | -10.4 ± 14.9 | 2.2 ± 10.4 |
| PDLB at Week 48 | -8.5 ± 13.9 | -0.4 ± 1.5 | -3.3 ± 23.5 | 1.7 ± 3.7 |
| Week 52 | 0.1 ± 17.0 | -9.7 ± 11.7 | -4.9 ± 13.5 | 2.7 ± 8.3 |
| Week 64 | -5.6 ± 18.4 | -8.3 ± 10.8 | -0.2 ± 22.5 | 3.9 ± 11.0 |
| PDLB at Week 72 | — | — | — | 7.1 ± NA |
| Week 76 | -11.2 ± 18.2 | -11.4 ± 13.5 | 0.7 ± 18.1 | 8.0 ± 13.3 |
| Week 88 | -12.5 ± 15.9 | -19.6 ± 27.8 | 3.2 ± 30.3 | 10.6 ± 9.5 |
| PDLB at Week 96 | — | -13.9 ± 15.7 | 2.9 ± NA | 7.6 ± 22.6 |
| Week 100 | -19.4 ± 19.4 | -13.6 ± 21.2 | -2.5 ± 3.6 | 10.1 ± 13.4 |
| Week 112 | -5.6 ± NA | -6.9 ± 13.8 | -2.4 ± 5.5 | 5.7 ± 15.6 |
| Week 124 | — | -4.8 ± 6.7 | 5.8 ± NA | 4.7 ± 10.5 |
| Week 136 | — | — | 2.9 ± NA | 6.8 ± 29.3 |
| Week 148 | — | — | 21.7 ± NA | 11.5 ± 30.8 |
| Week 160 | — | — | — | 26.0 ± 30.0 |
| Early Termination | — | — | 4.6 ± 26.1 | — |
| End of Study | 7.8 ± 18.2 | -7.2 ± 1.8 | 7.1 ± 13.9 | 5.3 ± 12.3 |
PDLB=post-dose liver biopsy
| U/L | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 2.8 ± 11.48 | -4.3 ± 5.90 | -9.1 ± 16.06 | 7.0 ± 14.88 |
| Week 16 + 24 H | -3.7 ± 16.80 | -4.8 ± 4.35 | -4.3 ± 4.93 | 1.1 ± 4.62 |
| Week 28 | -3.5 ± 11.99 | -5.3 ± 5.57 | -4.1 ± 9.65 | 0.6 ± 8.47 |
| Week 40 | 5.3 ± 31.24 | -3.8 ± 9.29 | 0.9 ± 16.88 | 0.6 ± 7.69 |
| PDLB at Week 48 | -13.5 ± 23.67 | -5.3 ± 4.16 | -5.3 ± 10.17 | -0.5 ± 10.48 |
| Week 52 | 7.3 ± 36.39 | -4.3 ± 11.13 | 6.8 ± 27.79 | 1.7 ± 6.64 |
| Week 64 | -16.0 ± 13.22 | -13.0 ± 14.14 | 2.7 ± 19.04 | 9.3 ± 22.13 |
| PDLB at Week 72 | — | — | — | -3.0 ± NA |
| Week 76 | -20.3 ± 28.36 | -13.3 ± 15.48 | -3.3 ± 11.04 | -0.3 ± 10.19 |
| Week 88 | -17.0 ± 29.51 | -19.0 ± 25.46 | 2.0 ± 7.81 | 7.2 ± 4.97 |
| PDLB at Week 96 | — | -25.5 ± 14.85 | 5.0 ± NA | 3.5 ± 0.71 |
| Week 100 | -25.0 ± 28.28 | -24.5 ± 21.92 | 6.5 ± 4.95 | -2.3 ± 14.29 |
| Week 112 | 0.0 ± NA | -21.5 ± 9.19 | 5.5 ± 4.95 | 4.3 ± 10.41 |
| Week 124 | — | -50.4 ± 2.6 | 8.0 ± NA | 1.7 ± 9.61 |
| Week 136 | — | — | 7.0 ± NA | 5.0 ± 7.55 |
| Week 148 | — | — | 10.0 ± NA | -0.3 ± 11.59 |
| Week 160 | — | — | — | 3.0 ± 4.24 |
| Early Termination | — | — | 5.0 ± 4.24 | — |
| End of Study | 22.5 ± 45.68 | -0.5 ± 0.71 | -19.5 ± 27.58 | 0.6 ± 5.59 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 5.9 ± 18.9 | -9.7 ± 12.7 | -14.8 ± 18.5 | 13.9 ± 31.0 |
| Week 16 + 24 H | 0.8 ± 32.2 | -9.1 ± 8.6 | -13.2 ± 13.6 | 4.7 ± 15.4 |
| Week 28 | -2.2 ± 21.5 | -12.0 ± 11.7 | -3.2 ± 22.2 | 6.8 ± 21.5 |
| Week 40 | 14.4 ± 52.4 | -6.4 ± 18.3 | -1.7 ± 31.6 | 7.4 ± 14.4 |
| PDLB at Week 48 | -8.9 ± 36.3 | -13.3 ± 7.2 | -10.4 ± 30.9 | 8.1 ± 17.6 |
| Week 52 | 26.7 ± 69.5 | -3.5 ± 25.1 | 6.2 ± 35.2 | 5.1 ± 15.3 |
| Week 64 | -23.0 ± 6.7 | -22.8 ± 17.8 | 20.7 ± 69.3 | 13.1 ± 24.9 |
| PDLB at Week 72 | — | — | — | -6.7 ± NA |
| Week 76 | -22.2 ± 13.6 | -23.1 ± 18.9 | -0.9 ± 38.4 | 9.5 ± 13.3 |
| Week 88 | 13.7 ± 21.1 | -26.8 ± 34.7 | 15.6 ± 39.5 | 17.9 ± 15.1 |
| PDLB at Week 96 | — | -42.0 ± 11.2 | 25.0 ± NA | 11.9 ± 2.7 |
| Week 100 | -23.4 ± 11.7 | -38.0 ± 24.8 | 33.8 ± 22.9 | 6.1 ± 24.2 |
| Week 112 | 0.0 ± NA | -36.5 ± 3.4 | 28.4 ± 23.5 | 16.0 ± 32.9 |
| Week 124 | — | -50.4 ± 2.6 | 40.0 ± NA | 8.1 ± 28.7 |
| Week 136 | — | — | 35.0 ± NA | 18.0 ± 23.4 |
| Week 148 | — | — | 50.0 ± NA | 2.9 ± 33.3 |
| Week 160 | — | — | — | 10.0 ± 14.1 |
| Early Termination | — | — | 30.7 ± 32.1 | — |
| End of Study | 39.2 ± 78.5 | -2.2 ± 3.1 | -17.1 ± 24.2 | 6.7 ± 18.8 |
PDLB=post-dose liver biopsy
| mg/dL | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 0.079 ± 0.146 | 0.098 ± 0.369 | -0.051 ± 0.241 | -0.004 ± 0.208 |
| Week 16 + 24 H | 0.060 ± 0.075 | 0.163 ± 0.456 | -0.040 ± 0.182 | -0.118 ± 0.105 |
| Week 28 | 0.109 ± 0.149 | 0.171 ± 0.470 | 0.053 ± 0.230 | 0.012 ± 0.272 |
| Week 40 | 0.083 ± 0.115 | 0.164 ± 0.437 | 0.017 ± 0.092 | 0.062 ± 0.434 |
| PDLB at Week 48 | 0.043 ± 0.109 | -0.070 ± 0.594 | 0.098 ± 0.252 | -0.085 ± 0.178 |
| Week 52 | -0.023 ± 0.203 | 0.129 ± 0.362 | 0.086 ± 0.165 | 0.099 ± 0.230 |
| Week 64 | 0.020 ± 0.210 | 0.188 ± 0.235 | 0.006 ± 0.208 | -0.086 ± 0.188 |
| PDLB at Week 72 | — | — | — | -0.420 ± NA |
| Week 76 | 0.110 ± 0.105 | 0.248 ± 0.357 | -0.043 ± 0.206 | -0.018 ± 0.198 |
| Week 88 | 0.247 ± 0.375 | 0.105 ± 0.035 | 0.002 ± 0.131 | -0.050 ± 0.131 |
| PDLB at Week 96 | — | 0.020 ± 0.127 | 0.170 ± NA | 0.065 ± 0.035 |
| Week 100 | -0.040 ± 0.099 | -0.055 ± 0.106 | 0.090 ± 0.042 | 0.003 ± 0.203 |
| Week 112 | -0.020 ± NA | -0.010 ± 0.269 | 0.100 ± 0.141 | -0.060 ± 0.249 |
| Week 124 | — | -0.190 ± 0.071 | 0.130 ± NA | -0.037 ± 0.085 |
| Week 136 | — | — | 0.100 ± NA | 0.003 ± 0.185 |
| Week 148 | — | — | 0.070 ± NA | -0.087 ± 0.199 |
| Week 160 | — | — | — | -0.090 ± 0.028 |
| Early Termination | — | — | -0.010 ± 0.014 | — |
| End of Study | 0.170 ± 0.123 | 0.050 ± 0.113 | 0.025 ± 0.205 | 0.154 ± 0.082 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 19.2 ± 38.5 | 15.6 ± 41.7 | 3.4 ± 44.1 | 1.0 ± 28.0 |
| Week 16 + 24 H | 16.4 ± 19.2 | 25.3 ± 49.7 | 3.1 ± 33.1 | -16.3 ± 12.6 |
| Week 28 | 26.7 ± 36.1 | 27.8 ± 51.4 | 15.8 ± 36.8 | 1.3 ± 37.5 |
| Week 40 | 20.6 ± 27.8 | 30.2 ± 51.4 | 10.0 ± 21.6 | 7.8 ± 46.4 |
| PDLB at Week 48 | 11.8 ± 27.8 | 10.8 ± 68.2 | 36.5 ± 52.2 | -10.9 ± 29.4 |
| Week 52 | -8.3 ± 36.6 | 27.5 ± 48.8 | 25.4 ± 29.4 | 15.5 ± 36.4 |
| Week 64 | 10.3 ± 51.0 | 28.5 ± 38.0 | 10.0 ± 35.7 | -13.3 ± 28.1 |
| PDLB at Week 72 | — | — | — | -60.0 ± NA |
| Week 76 | 18.1 ± 16.1 | 40.1 ± 57.1 | 0.3 ± 31.6 | -1.0 ± 33.2 |
| Week 88 | 38.0 ± 53.7 | 13.1 ± 1.7 | 5.4 ± 29.3 | -7.6 ± 21.4 |
| PDLB at Week 96 | — | 0.8 ± 15.9 | 39.5 ± NA | 9.2 ± 1.7 |
| Week 100 | -11.9 ± 25.2 | -8.6 ± 15.3 | 25.1 ± 4.0 | 0.4 ± 31.6 |
| Week 112 | -5.4 ± NA | -5.0 ± 35.1 | 37.0 ± 52.4 | -5.8 ± 30.8 |
| Week 124 | — | -23.6 ± 3.9 | 30.2 ± NA | -5.7 ± 12.4 |
| Week 136 | — | — | 23.3 ± NA | 4.4 ± 25.2 |
| Week 148 | — | — | 16.3 ± NA | -7.6 ± 29.7 |
| Week 160 | — | — | — | -13.4 ± 0.9 |
| Early Termination | — | — | -2.9 ± 4.2 | — |
| End of Study | 41.8 ± 36.4 | 11.5 ± 26.4 | 25.0 ± 69.2 | 26.8 ± 16.6 |
PDLB=post-dose liver biopsy
| mg/dL | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 0.016 ± 0.049 | -0.006 ± 0.095 | 0.005 ± 0.094 | 0.010 ± 0.061 |
| Week 16 + 24 H | 0.013 ± 0.029 | 0.055 ± 0.157 | -0.030 ± 0.081 | -0.028 ± 0.041 |
| Week 28 | 0.029 ± 0.055 | 0.039 ± 0.140 | 0.004 ± 0.062 | 0.008 ± 0.073 |
| Week 40 | 0.026 ± 0.050 | 0.045 ± 0.160 | -0.005 ± 0.063 | 0.020 ± 0.125 |
| PDLB at Week 48 | -0.005 ± 0.041 | -0.080 ± 0.210 | 0.007 ± 0.087 | -0.038 ± 0.065 |
| Week 52 | -0.024 ± 0.080 | 0.034 ± 0.107 | 0.015 ± 0.052 | 0.031 ± 0.058 |
| Week 64 | -0.008 ± 0.081 | 0.053 ± 0.061 | -0.007 ± 0.076 | -0.019 ± 0.043 |
| PDLB at Week 72 | — | — | — | -46.2 ± NA |
| Week 76 | 0.027 ± 0.029 | 0.098 ± 0.069 | -0.033 ± 0.073 | 0.027 ± 0.057 |
| Week 88 | 0.053 ± 0.114 | 0.070 ± 0.014 | -0.007 ± 0.043 | 0.012 ± 0.026 |
| PDLB at Week 96 | — | 0.030 ± NA | 0.080 ± NA | 0.045 ± 0.035 |
| Week 100 | 0.000 ± 0.028 | 0.010 ± 0.014 | 0.050 ± 0.028 | 0.018 ± 0.052 |
| Week 112 | 0.020 ± NA | 0.025 ± 0.049 | 0.055 ± 0.035 | 0.007 ± 0.061 |
| Week 124 | — | -0.040 ± 0.057 | 0.070 ± NA | 0.020 ± 0.035 |
| Week 136 | — | — | 0.030 ± NA | 0.013 ± 0.046 |
| Week 148 | — | — | 0.050 ± NA | -0.003 ± 0.090 |
| Week 160 | — | — | — | 0.015 ± 0.007 |
| Early Termination | — | — | 0.005 ± 0.007 | — |
| End of Study | 0.050 ± 0.060 | 0.010 ± 0.028 | 0.028 ± 0.138 | 0.053 ± 0.044 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | 5.9 ± 30.1 | 1.5 ± 31.2 | 29.1 ± 67.6 | 15.1 ± 58.9 |
| Week 16 + 24 H | 11.0 ± 16.4 | 22.4 ± 50.9 | -0.1 ± 33.0 | -8.8 ± 17.0 |
| Week 28 | 19.0 ± 28.3 | 15.4 ± 37.3 | 21.2 ± 61.9 | 10.1 ± 44.6 |
| Week 40 | 17.9 ± 27.5 | 16.7 ± 44.9 | 15.5 ± 47.6 | 14.3 ± 50.2 |
| PDLB at Week 48 | 2.9 ± 19.5 | -9.9 ± 63.0 | 19.3 ± 48.7 | -11.9 ± 23.9 |
| Week 52 | -12.1 ± 34.3 | 17.8 ± 35.1 | 25.1 ± 47.0 | 19.6 ± 38.5 |
| Week 64 | 4.4 ± 39.7 | 18.9 ± 26.7 | 8.2 ± 37.3 | -8.6 ± 16.7 |
| PDLB at Week 72 | — | — | — | -46.2 ± NA |
| Week 76 | 9.9 ± 7.4 | 33.4 ± 20.2 | -5.4 ± 30.0 | 11.4 ± 21.5 |
| Week 88 | 18.2 ± 35.0 | 24.9 ± 14.0 | -3.3 ± 30.3 | 5.6 ± 12.1 |
| PDLB at Week 96 | — | 7.5 ± NA | 53.3 ± NA | 17.1 ± 10.0 |
| Week 100 | -3.8 ± 16.3 | 4.3 ± 6.1 | 37.0 ± 13.7 | 7.5 ± 23.2 |
| Week 112 | 15.4 ± NA | 5.3 ± 13.7 | 46.4 ± 37.3 | 4.1 ± 22.5 |
| Week 124 | — | -10.0 ± 14.1 | 46.7 ± NA | 7.7 ± 13.3 |
| Week 136 | — | — | 20.0 ± NA | 7.2 ± 18.3 |
| Week 148 | — | — | 33.3 ± NA | 3.4 ± 38.5 |
| Week 160 | — | — | — | 6.7 ± 4.6 |
| Early Termination | — | — | 2.4 ± 3.4 | — |
| End of Study | 34.3 ± 45.6 | 5.4 ± 14.7 | 96.1 ± 185.5 | 40.8 ± 46.7 |
PDLB=post-dose liver biopsy
| ratio | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -0.012 ± 0.054 | -0.006 ± 0.093 | 0.011 ± 0.068 | 0.055 ± 0.180 |
| Week 16 + 24 H | 0.047 ± 0.111 | -0.085 ± 0.093 | -0.017 ± 0.117 | 0.036 ± 0.104 |
| Week 28 | -0.054 ± 0.148 | -0.059 ± 0.109 | -0.040 ± 0.107 | -0.014 ± 0.167 |
| Week 40 | -0.021 ± 0.113 | -0.024 ± 0.099 | -0.022 ± 0.125 | 0.034 ± 0.143 |
| PDLB at Week 48 | -0.038 ± 0.054 | -0.067 ± 0.150 | -0.023 ± 0.121 | 0.022 ± 0.048 |
| Week 52 | -0.094 ± 0.139 | -0.053 ± 0.057 | -0.034 ± 0.076 | -0.002 ± 0.076 |
| Week 64 | -0.038 ± 0.089 | -0.100 ± 0.082 | -0.043 ± 0.130 | 0.012 ± 0.055 |
| PDLB at Week 72 | — | — | — | 0.040 ± NA |
| Week 76 | -0.033 ± 0.049 | -0.110 ± 0.130 | -0.065 ± 0.136 | 0.020 ± 0.046 |
| Week 88 | -0.053 ± 0.040 | -0.225 ± 0.177 | -0.004 ± 0.083 | 0.038 ± 0.026 |
| PDLB at Week 96 | — | -0.195 ± 0.134 | 0.090 ± NA | 0.045 ± 0.078 |
| Week 100 | 0.000 ± 0.014 | -0.225 ± 0.163 | -0.020 ± 0.099 | 0.063 ± 0.045 |
| Week 112 | 0.050 ± NA | -0.240 ± 0.184 | 0.035 ± 0.078 | 0.047 ± 0.083 |
| Week 124 | — | -0.175 ± 0.247 | 0.050 ± NA | 0.053 ± 0.021 |
| Week 136 | — | — | 0.070 ± NA | 0.043 ± 0.032 |
| Week 148 | — | — | 0.080 ± NA | 0.040 ± 0.026 |
| Week 160 | — | — | — | 0.070 ± 0.042 |
| Early Termination | — | — | 0.045 ± 0.092 | — |
| End of Study | -0.115 ± 0.170 | -0.045 ± 0.049 | -0.035 ± 0.021 | -0.106 ± 0.149 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 16 | -1.0 ± 4.8 | -0.7 ± 7.7 | 1.2 ± 6.4 | 2.6 ± 8.6 |
| Week 16 + 24 H | 4.4 ± 10.3 | -7.0 ± 6.9 | -1.0 ± 10.2 | 3.5 ± 9.9 |
| Week 28 | -3.9 ± 11.8 | -4.9 ± 8.5 | -3.3 ± 9.1 | 1.2 ± 8.7 |
| Week 40 | -1.2 ± 9.6 | -1.6 ± 7.8 | -1.6 ± 11.3 | 3.7 ± 13.0 |
| PDLB at Week 48 | -3.2 ± 4.7 | -5.5 ± 13.3 | -1.5 ± 10.3 | 2.2 ± 4.8 |
| Week 52 | -7.7 ± 10.2 | -4.7 ± 4.9 | -2.9 ± 6.3 | 0.3 ± 6.9 |
| Week 64 | -3.2 ± 7.9 | -8.4 ± 7.1 | -3.2 ± 11.4 | 1.3 ± 5.3 |
| PDLB at Week 72 | — | — | — | 3.9 ± NA |
| Week 76 | -2.8 ± 4.0 | -8.8 ± 9.9 | -5.3 ± 11.8 | 2.0 ± 4.6 |
| Week 88 | -4.7 ± 3.1 | -17.9 ± 12.5 | -0.3 ± 8.0 | 3.7 ± 2.4 |
| PDLB at Week 96 | — | -15.6 ± 9.2 | 9.0 ± NA | 4.6 ± 7.8 |
| Week 100 | 0.0 ± 1.4 | -18.0 ± 11.3 | -1.8 ± 9.6 | 6.2 ± 4.5 |
| Week 112 | 4.9 ± NA | -19.1 ± 12.9 | 3.5 ± 7.7 | 4.7 ± 8.4 |
| Week 124 | — | -13.4 ± 18.9 | 5.0 ± NA | 5.3 ± 2.1 |
| Week 136 | — | — | 7.0 ± NA | 4.3 ± 3.3 |
| Week 148 | — | — | 8.0 ± NA | 3.9 ± 2.5 |
| Week 160 | — | — | — | 7.0 ± 4.3 |
| Early Termination | — | — | 4.8 ± 9.4 | — |
| End of Study | -9.1 ± 12.7 | -4.3 ± 4.9 | -3.6 ± 2.0 | -5.8 ± 4.7 |
PDLB=post-dose liver biopsy
| μg/mL | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 2 | -125.511 ± 59.955 | -156.714 ± 58.127 | -169.044 ± 40.328 | 16.929 ± 37.723 |
| Week 4 | -146.267 ± 68.511 | -178.413 ± 58.821 | -181.389 ± 41.857 | -0.429 ± 18.826 |
| Week 6 | -176.100 ± 47.242 | -192.719 ± 65.087 | -188.781 ± 43.539 | 7.000 ± 26.712 |
| Week 16 | -158.650 ± 50.266 | -185.213 ± 58.059 | -182.240 ± 45.710 | 10.286 ± 29.374 |
| Week 28 | -123.288 ± 62.112 | -174.275 ± 57.293 | -175.136 ± 52.838 | -0.500 ± 25.035 |
| Week 40 | -122.288 ± 70.057 | -165.763 ± 59.312 | -164.629 ± 63.830 | 1.429 ± 20.137 |
| PDLB at Week 48 | -189.850 ± 64.556 | -150.900 ± 17.521 | -194.535 ± 51.128 | 14.333 ± 38.754 |
| Week 52 | -116.188 ± 72.983 | -157.300 ± 56.023 | -165.741 ± 64.535 | -13.643 ± 36.527 |
| Week 64 | -187.325 ± 94.397 | -191.150 ± 80.589 | -190.284 ± 45.070 | 0.333 ± 27.208 |
| PDLB at Week 72 | — | — | — | -6.00 ± NA |
| Week 76 | -164.067 ± 65.875 | -189.225 ± 91.259 | -177.060 ± 49.718 | -9.500 ± 20.907 |
| Week 88 | -142.767 ± 89.632 | -260.200 ± 82.166 | -186.116 ± 44.539 | -1.800 ± 28.490 |
| PDLB at Week 96 | — | -271.100 ± 90.793 | -194.160 ± NA | -35.000 ± 15.556 |
| Week 100 | -204.650 ± 18.597 | -244.100 ± 91.358 | -187.650 ± 3.323 | -60.725 ± 84.824 |
| Week 112 | -233.000 ± NA | -263.100 ± 91.358 | -182.550 ± 3.182 | -22.333 ± 22.679 |
| Week 124 | — | -237.650 ± 102.743 | -183.000 ± NA | -26.000 ± 22.271 |
| Week 136 | — | — | -183.300 ± NA | -8.000 ± 22.650 |
| Week 148 | — | — | -89.1 ± NA | 9.333 ± 11.719 |
| Week 160 | — | — | — | 7.500 ± 9.192 |
| Early Termination | — | — | -192.240 ± 81.657 | — |
| End of Study | -42.750 ± 7.089 | -103.533 ± 3.443 | -39.000 ± 1.414 | 19.750 ± 30.966 |
PDLB=post-dose liver biopsy
| percentage change | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| Week 2 | -50.8 ± 21.9 | -69.9 ± 11.4 | -85.5 ± 4.8 | 10.0 ± 23.8 |
| Week 4 | -60.0 ± 24.6 | -82.2 ± 7.1 | -91.8 ± 2.5 | 0.5 ± 8.7 |
| Week 6 | -71.9 ± 14.0 | -88.4 ± 5.0 | -95.5 ± 1.9 | 3.4 ± 11.4 |
| Week 16 | -62.4 ± 17.0 | -85.7 ± 7.6 | -91.9 ± 5.8 | 4.3 ± 12.2 |
| Week 28 | -48.2 ± 20.6 | -80.6 ± 7.9 | -87.6 ± 10.4 | 0.1 ± 11.2 |
| Week 40 | -48.3 ± 23.4 | -76.5 ± 10.5 | -81.3 ± 18.8 | 0.3 ± 9.2 |
| PDLB at Week 48 | -73.9 ± 16.7 | -89.2 ± 2.5 | -93.9 ± 5.0 | 8.7 ± 19.0 |
| Week 52 | -45.9 ± 24.7 | -73.0 ± 12.9 | -82.1 ± 20.5 | -5.3 ± 14.9 |
| Week 64 | -70.1 ± 23.5 | -77.6 ± 9.5 | -92.2 ± 5.7 | 2.1 ± 12.3 |
| PDLB at Week 72 | — | — | — | -2.4 ± NA |
| Week 76 | -71.8 ± 19.6 | -75.1 ± 9.0 | -88.8 ± 10.1 | -2.4 ± 9.3 |
| Week 88 | -60.1 ± 32.6 | -77.8 ± 7.2 | -90.3 ± 6.3 | 0.5 ± 11.4 |
| PDLB at Week 96 | — | -80.9 ± 9.1 | -95.6 ± NA | -11.7 ± 4.2 |
| Week 100 | -82.5 ± 10.1 | -72.5 ± 11.2 | -93.8 ± 0.3 | -21.3 ± 29.6 |
| Week 112 | -91.7 ± NA | -78.4 ± 9.9 | -91.3 ± 3.5 | -8.4 ± 9.2 |
| Week 124 | — | -70.1 ± 15.2 | -90.1 ± NA | -9.9 ± 9.1 |
| Week 136 | — | — | -90.3 ± NA | -3.2 ± 8.8 |
| Week 148 | — | — | -89.1 ± NA | 3.1 ± 4.1 |
| Week 160 | — | — | — | 2.4 ± 2.9 |
| Early Termination | — | — | -91.7 ± 8.5 | — |
| End of Study | -18.0 ± 2.7 | -53.8 ± 6.6 | -23.4 ± 0.1 | 9.1 ± 12.4 |
| ng/mL | Fazirsiran 25 mg: Participants With No Fibrosis | Fazirsiran 25 mg: Participants With Fibrosis | Fazirsiran 100 mg: Participants With No Fibrosis | Fazirsiran 100 mg: Participants With Fibrosis | Fazirsiran 200 mg: Participants With No Fibrosis | Fazirsiran 200 mg: Participants With Fibrosis |
|---|---|---|---|---|---|---|
| Day 1, Pre-Dose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Day 1, 1 hour (h) | 29.9 ± 75.6 | 50.6 ± 66.8 | 190.0 ± 17.9 | 173.0 ± 25.7 | 495.0 ± 71.8 | 356.0 ± 75.9 |
| Day 1, 2h | 35.0 ± 83.0 | 60.7 ± 72.5 | 208.0 ± 11.6 | 199.0 ± 32.2 | 537.0 ± 81.9 | 471.0 ± 56.5 |
| Day 1, 24h | 9.92 ± 99.6 | 6.33 ± 176.0 | 69.0 ± 88.4 | 26.6 ± 59.1 | 11.7 ± 17100 | 27.7 ± 612.0 |
| Week 16, Pre-Dose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Week 16, 1h | — | 38.1 ± 75.3 | — | 38.1 ± 75.3 | — | 396.0 ± 64.9 |
| Week 16, 2h | — | 45.1 ± 70.1 | — | 45.1 ± 70.1 | — | 487.0 ± 62.5 |
| Week 16, 24h | — | 3.64 ± 123.0 | — | 3.64 ± 123.0 | — | 104.0 ± 26.2 |
PDLB=post-dose liver biopsy
| Participants | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg |
|---|---|---|---|
| Baseline | 0 | 2 | 2 |
| Week 4 | 0 | 1 | 2 |
| Week 16 | 0 | 1 | 2 |
| Week 28 | 0 | 2 | 1 |
| Week 40 | 0 | 2 | 2 |
| PDLB at Week 48 | 0 | — | 0 |
| Week 52 | 0 | 1 | 0 |
| Week 64 | 0 | 0 | 0 |
| Week 76 | 0 | 1 | 0 |
| Week 88 | 0 | 0 | 0 |
| PDLB at Week 96 | — | — | 0 |
| Week 100 | 0 | 0 | 0 |
| Week 112 | 0 | 0 | 1 |
| Week 124 | — | 0 | 1 |
| Week 136 | — | — | 1 |
| Week 148 | — | — | 1 |
| Early Termination | — | — | 0 |
The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. The stage represents the amount of fibrosis or scarring: 0= no fibrosis; 1=portal fibrosis without septa; 2=portal fibrosis with few septa; 3=numerous septa without cirrhosis; 4=cirrhosis. A higher score indicates a worse condition.
| percentage of participants | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo |
|---|---|---|---|---|
| >= 1-point improvement from baseline | 66.7 | 40.0 | 50.0 | 37.5 |
| no change from baseline | 25.0 | 60.0 | 14.3 | 44.4 |
| >= 1-point worsening from baseline | 25.0 | 0.0 | 42.9 | 22.2 |
Collected over Participants without fibrosis: for a maximum duration of follow up of 66 weeks. Participants with evidence of fibrosis: for a maximum duration of follow up of 210 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fazirsiran 25 mg | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Fazirsiran 100 mg | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Fazirsiran 200 mg | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| Placebo | 0/14 (0%) | 3/14 (21.4%) | 14/14 (100%) |
| Fazirsiran 25 mg DB/200 mg OL | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Fazirsiran 100 mg DB/200 mg OL | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Fazirsiran 200 mg DB/200 mg OL | 0/5 (0%) | 1/5 (20%) | 3/5 (60%) |
| Placebo DB / Fazirsiran 200 mg OL | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Event | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Fazirsiran 25 mg DB/200 mg OL | Fazirsiran 100 mg DB/200 mg OL | Fazirsiran 200 mg DB/200 mg OL | Placebo DB / Fazirsiran 200 mg OL |
|---|---|---|---|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/9 | 0/8 | 0/9 | 1/14 | 1/4 | 1/5 | 1/5 | 1/9 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/9 | 0/8 | 0/9 | 0/14 | 1/4 | 0/5 | 0/5 | 0/9 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 0/9 | 0/8 | 0/9 | 0/14 | 1/4 | 0/5 | 0/5 | 0/9 |
| Infective exacerbation of bronchiectasisInfections and infestations | 0/9 | 0/8 | 2/9 | 0/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| Clostridium difficile infectionInfections and infestations | 0/9 | 0/8 | 0/9 | 0/14 | 0/4 | 0/5 | 1/5 | 0/9 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 0/8 | 0/9 | 0/14 | 0/4 | 1/5 | 0/5 | 0/9 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/9 | 0/8 | 1/9 | 0/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 0/8 | 0/9 | 0/14 | 0/4 | 0/5 | 0/5 | 1/9 |
| InfluenzaInfections and infestations | 0/9 | 0/8 | 0/9 | 1/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| Wound infection staphylococcalInfections and infestations | 0/9 | 0/8 | 0/9 | 1/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| Event | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Fazirsiran 25 mg DB/200 mg OL | Fazirsiran 100 mg DB/200 mg OL | Fazirsiran 200 mg DB/200 mg OL | Placebo DB / Fazirsiran 200 mg OL |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/9 | 2/8 | 7/9 | 2/14 | 0/4 | 1/5 | 1/5 | 2/9 |
| HeadacheNervous system disorders | 4/9 | 1/8 | 2/9 | 4/14 | 0/4 | 2/5 | 0/5 | 0/9 |
| NauseaGastrointestinal disorders | 1/9 | 0/8 | 1/9 | 3/14 | 0/4 | 2/5 | 0/5 | 1/9 |
| Procedural painInjury, poisoning and procedural complications | 2/9 | 2/8 | 3/9 | 3/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| PalpitationsCardiac disorders | 0/9 | 2/8 | 0/9 | 0/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| Ear discomfortEar and labyrinth disorders | 0/9 | 0/8 | 0/9 | 0/14 | 1/4 | 0/5 | 0/5 | 0/9 |
| Ear painEar and labyrinth disorders | 0/9 | 0/8 | 0/9 | 0/14 | 1/4 | 0/5 | 0/5 | 0/9 |
| Abdominal pain upperGastrointestinal disorders | 0/9 | 2/8 | 0/9 | 0/14 | 0/4 | 0/5 | 0/5 | 0/9 |
| FatigueGeneral disorders | 1/9 | 1/8 | 0/9 | 2/14 | 1/4 | 1/5 | 0/5 | 0/9 |
| Injection site erythemaGeneral disorders | 0/9 | 1/8 | 0/9 | 2/14 | 1/4 | 0/5 | 0/5 | 0/9 |
| Age, Continuous(years) | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52.6 ± 15.56 | 47.9 ± 12.25 | 51.6 ± 9.44 | 57.4 ± 9.05 | 53.1 ± 12.33 |
| Sex: Female, Male(Participants) | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 6 | 6 | 5 | 22 |
| Male | 4 | 2 | 3 | 9 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 2 | 3 |
| Not Hispanic or Latino | 9 | 7 | 9 | 12 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| White | 9 | 8 | 9 | 14 | 40 |
| Fibrosis Status at Screening(Participants) | Fazirsiran 25 mg | Fazirsiran 100 mg | Fazirsiran 200 mg | Placebo | Total |
|---|---|---|---|---|---|
| Fibrosis at Screening | 4 | 5 | 7 | 9 | 25 |
| No fibrosis at Screening | 5 | 3 | 2 | 5 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Nov 2021, 27 months.
Results were first posted in Dec 2024, 3 years 1 month after primary completion. A results delay was requested in Oct 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fazirsiran
alpha 1-Antitrypsin Deficiency →